Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (373)
  2. Journal Article (219)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (631)
  2. Solid Tumor Oncology Division (631)
  3. Thoracic Oncology (631)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (187)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Marc Ladanyi (121)
  2. Mark Kris (89)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (16)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (77)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (631)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)
    Meeting Abstract

    Cabanillas, M. E.; Lin, J. J.; Brose, M. S.; McDermott, R. S.; Almubarak, M.; Bauman, J. R.; Casanova, M.; Kummar, S.; Lee, S. H.; Leyvraz, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies
    Meeting Abstract

    Drilon, A. E.; Dziadziuszko, R.; Camidge, D. R.; Lin, J. J.; Besse, B.; Kim, S. W.; Lee, K. H.; Solomon, B. J.; Nagasaka, M.; Goto, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer
    Meeting Abstract

    Drilon, A. E.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Moreno, V.; Leyvraz, S.; Dubashi, B.; Haresh, K. P.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study
    Meeting Abstract

    Brose, M. S.; Westphalen, C. B.; Kehl, K. L.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors
    Meeting Abstract

    Liu, D.; Keller-Evans, R. B.; Schrock, A. B.; Drilon, A. E.; Jee, J.; Li, B. T.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Standardizing radiologic reporting of response to improve the patient experience: Comparing response categories of RECIST 1.1 and a novel, real-world, standardized, oncologic response lexicon derived from clinical radiology reports
    Meeting Abstract

    Chen, M. F.; Ma, W.; Caravella, B. A.; Harada, G.; Gangai, N.; Grimaldi, G.; Waksmundzki, A.; Trevenen, W.; Kohlasch, K.; Reynolds, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Diverging acquired resistance evolutionary pathways in fusion-positive patients treated with tyrosine kinase inhibitors
    Meeting Abstract

    Repetto, M.; Selenica, P.; Gazzo, A.; Richards, A. L.; Reis-Filho, J. S.; Jee, J.; Donoghue, M.; Weigelt, B.; Drilon, A. E.; Choudhury, N. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Association of ERBB2 extrachromosomal DNA (ecDNA) with first-line HER2-targeted treatment outcomes in advanced esophagogastric adenocarcinoma (EGC)
    Meeting Abstract

    Tsai, C.; Suman, S.; Chu, C.; Chou, J. F.; Krein, P. M.; Capanu, M.; Ilson, D. H.; Ku, G. Y.; Janjigian, Y. Y.; Drilon, A. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types
    Meeting Abstract

    Gormally, M.; Repetto, M.; Jee, J.; Chang, J. C.; Selenica, P.; Gazzo, A.; Richards, A. L.; Donoghue, M.; Aghajanian, C.; Reis-Filho, J. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort
    Meeting Abstract

    Desilets, A.; Repetto, M.; Kemel, Y.; Khurram, A.; Mandelker, D.; Bandlamudi, C.; Novak, B.; Velilla, C.; Selenica, P.; Richards, A. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save